ReviewClinical transplantation2017
Direct oral anticoagulant considerations in solid organ transplantation: A review.
Review in Clinical transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 53 citations in OpenAlex.
- Coagulation Abnormalities in Liver Cirrhosis: Diagnostic and Therapeutic Approaches.Medicina (Kaunas, Lithuania) · 2026Review
- Apixaban in Abdominal Transplantation: An Antithrombotic Stewardship Assessment.Advances in hematology · 2026Article
- Out-of-pocket costs for direct oral anticoagulants and prescription abandonment among patients with nonvalvular atrial fibrillation or venous thromboembolism.Journal of managed care & specialty pharmacy · 2025Article
- Direct Oral Anticoagulants in Patients With ESRD and Kidney Transplantation.Kidney international reports · 2025Review
- Article
- Oral Anticoagulants after Heart Transplantation-Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants.Journal of clinical medicine · 2023Article
- Youngest en-bloc kidney transplant recipient in India: defying the barriers and challenges with teamwork.BMJ case reports · 2023Article
- Safety and mortality outcomes for direct oral anticoagulants in renal transplant recipients.PloS one · 2023Article
- Drug Interactions Affecting Oral Anticoagulant Use.Circulation. Arrhythmia and electrophysiology · 2022Review
- Need for anticoagulation and use of direct oral anticoagulants in lung transplant recipients.Journal of thrombosis and thrombolysis · 2021Article
- Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Idarucizumab (PraxbindFuture science OA · 2021Article
- Assessment of direct oral anticoagulants administered as potentially inappropriate medications to elderly inpatients.International journal of clinical pharmacy · 2020Article
- Prothrombin Complex Concentrate in Liver Transplant Surgery: Correction of Therapeutic Anticoagulation and the Coagulopathy of End-Stage Liver Disease: Case Series.Frontiers in pharmacology · 2020Article
- Efficacy and safety of non-vitamin K antagonist oral anticoagulants post-kidney transplantation.World journal of transplantation · 2019Article
- Prophylaxis of Pulmonary Embolism in Kidney Transplant Recipients.Current urology reports · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
For more than 60 years, warfarin was the only oral anticoagulation agent available for use in the United States. In many recent clinical trials, several direct oral anticoagulants (DOACs) demonstrated similar efficacy with an equal or superior safety profile, with some other notable benefits. The DOACs have lower inter- and intrapatient variability, much shorter half-lives, and less known drug-drug and drug-food interactions as compared to warfarin. Despite these demonstrated benefits, the use of DOACs has not gained uniform acceptance because of lack of supportive data in special patient populations, including recipients of solid organ transplants maintained on immunosuppression. This review describes the properties of several novel DOACs including their pharmacology and mechanisms of action as they relate to use among solid organ transplant recipients. We have particularly focused on (i) dosing in patients with impaired renal and hepatic function; (ii) considerations for drug-drug interactions with immunosuppressive medications; and (iii) management of the anticoagulated patients at the time of unplanned surgery. The risks and benefits of the use of DOACs in solid organ transplant recipients should be carefully evaluated prior to the introduction of these agents in this highly distinct patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.